Clover’s respiratory combo vaccines secure Phase II wins in elderly recipients

Clover says the mid-stage results for both of its combination respiratory vaccines support their continued development. The biotech says the mid-stage results for both of its combination respiratory vaccines support their continued development. Clover says that its combination respiratory vaccine candidates could hold “best-in-class” potential as respiratory disease continues to place a significant burden on global public healthcare systems. Credit: PeopleImages / Shutterstock.com. Clover Biopharmaceuticals’ combination vaccines for respiratory diseases have posted positive data during a Phase II trial in older recipients – a development the Chinese biotech says could highlight its “best-in-class” protective capacity. In the multi-centre mid-stage study,…

Source: Clinical Trials Arena